{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-118973","form_type":"8-K","ticker":"PTPI","cik":"0001815903","company_name":"Petros Pharmaceuticals, Inc.","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.276291+00:00","generated_at":"2026-06-21T18:49:44.774894+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Petros Pharma Q3 net sales negative $1.4M, net loss $13.8M on excessive returns","bullets":["Net sales of -$1.4M vs $2.1M YoY; Prescription Medicines segment net sales -$2.1M due to expired product returns.","Gross profit -$1.7M (Q3 2021: $1.8M); SG&A reduced to $2.2M from $3.4M on cost-cutting.","Net loss widened to $13.8M from $1.7M; cash $11.2M vs $13.3M prior quarter.","FDA approved label expansion for STENDRA (avanafil) for ED in men post-radical prostatectomy.","Company shifts primary focus to over-the-counter access for STENDRA, citing improved shelf life."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-118973","json":"https://secwatch.observer/filing/0001104659-22-118973.json","markdown":"https://secwatch.observer/filing/0001104659-22-118973.md","text":"https://secwatch.observer/filing/0001104659-22-118973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815903/000110465922118973/0001104659-22-118973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815903/000110465922118973/tm2230572d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T18:49:44.774894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4687abf17a2b734652d40e9243b34258f85e1868","claim":"Petros Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue negative $1.4 million, net income $13.8 million.","evidence_excerpt":"and will manage cash prudently to achieve that goal,” concluded Mr. Boctor. Q3 2022 Financial Results Net sales for the third quarter ended September 30, 2022, were negative $1.4 million, comprised of negative $2.1 million of net sales from Prescription Medicines and $0.7 million of net sales from Medical Devices. This compares to net sales for the quarter ended","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815903/000110465922118973/0001104659-22-118973-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"negative $1.4 million"},{"label":"Net income","value":"$13.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}